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A higher concentration of high density lipoprotein cholesterol (HDL-C) in ex-smokers than smokers has consistently
been observed. Better evidence of quitting effects comes from within-subject changes. We extend an earlier meta-
analysis to quantify the reduction, and investigate variation by time quit and other factors. We conducted Medline
and Cochrane searches for studies measuring HDL-C in subjects while still smoking and later having quit. Using
unweighted and inverse-variance weighted regression analysis, we related changes (in mmol/l) to intra-measurement
period, and estimated time quit, and to study type, location and start year, age, sex, product smoked, validation of
quitting, baseline HDL-C, baseline and change in weight/BMI, and any study constraints on diet or exercise. Forty-five
studies were identified (17 Europe, 16 North America, 11 Asia, 1 Australia). Thirteen were observational, giving changes
over at least 12 months, with most involving >1000 subjects. Others were smoking cessation trials, 12 randomized and
20 non-randomized. These were often small (18 of <100 subjects) and short (14 of <10 weeks, the longest a year).
Thirty studies provided results for only one time interval. From 94 estimates of HDL-C change, the unweighted mean
was 0.107 (95% CI 0.085-0.128). The weighted mean 0.060 (0.044 to 0.075) was lower, due to smaller estimates in longer
term studies. Weighted means varied by time quit (0.083, 0.112, 0.111, 0.072, 0.058 and 0.040 for <3, 3 to <6, 6 to <13,
13 to <27, 27 to <52 and 52+ weeks, p=0.006). After adjustment for time quit, estimates varied by study constraint on
diet/exercise (p=0.003), being higher in studies requiring subjects to maintain their pre-quitting habits, but no other
clear differences were seen, with significant (p<0.05) increases following quitting being evident in all subgroups
studied, except where data were very limited. For both continuing and never smokers, the data are (except for two
large studies atypically showing significant HDL-C declines in both groups, and a smaller decline in quitters) consistent
with no change, and contrast markedly with the data for quitters. We conclude that quitting smoking increases HDL-C,
and that this increase occurs rapidly after quitting, with no clear pattern of change thereafter.
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It has long been known [1,2] that current smokers have
a lower concentration of high density lipoprotein choles-
terol (HDL-C) than do non-smokers. Evidence that ex-
smokers have higher HDL-C concentrations than do
current smokers (e.g. [3]) also exists, though partly based
on between-group comparisons, with current smokers
and quitters differing on other relevant variables. A
method of investigating how quitting affects HDL-C,
which better avoids confounding, uses within-subject esti-
mates of change. In 2003, Maeda et al. [4] reviewed evi-
dence of effects of quitting on lipid/ lipoprotein profiles,* Correspondence: PeterLee@pnlee.co.uk
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reproduction in any medium, provided the orusing data on within-subject changes. Their meta-analysis
for HDL-C, based on 29 studies with follow-up periods
from 30 days to 2 years or more, showed an increase fol-
lowing quitting of 0.100 (95% CI 0.074 to 0.127) mmol/l.
The estimates were highly heterogeneous (p<0.001),
though significant (p<0.05) variations were only seen by
gender (greater increases in females) and by baseline
HDL-C (greater increases for higher pre-quitting levels).
No significant variation was seen by study design, publica-
tion year or intra-measurement period (increases similar
for periods less or greater than 8 weeks).
Although more recent reviews have considered effects
of quitting on HDL-C (e.g. [5-7]), none involve an updated
meta-analysis. This review presents an updated meta-
analysis using data on changes, more fully investigatingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Of particular interest is quantifying how the increase var-
ies with time, some authors claiming “a complete and very
fast reversibility of changes after smoking cessation” [8]
and others an initial quite rapid “movement towards
normalization of HDL-C” which “will continue to progress
toward normal (non-smoking) levels as long as cessation
continues” [6]. Some studies reporting changes in quitters




Selection of studies and literature searches
For selected publications we examined abstracts, and
where necessary full text, to find studies satisfying these
inclusion criteria: (1) relevant to HDL-C and quitting;
(2) clinical trial, human experimental, or epidemiological
study; (3) prospective or longitudinal study; (4) at least
five subjects quitting; (5) not restricted to those with
coronary artery disease or taking antihyperlipidaemic
drugs; (6) smoking habits recorded and blood sample
taken concurrently on two or more occasions; (7) results
reported separately for quitters during the study; (8) re-
sults available relevant to the change in HDL-C following
quitting; (9) quitting for at least a day; and (10) results re-
late to conventional cigarette smoking.
Papers cited by Maeda et al. [4] were considered, the
Medline searches they conducted being updated to July
2012. These used the search terms “(smoking OR to-
bacco OR cigar) AND (tobacco use cessation OR to-
bacco use cessation products OR stop OR quit OR
cessation OR abstinence OR exsmokers) AND (choles-
terol OR triglycerides OR lipoprotein OR HDL)”. New
papers were then sought from Collaborative Trials
within the Cochrane Library using the same keywords,
from reference lists in accepted papers, and from an on-
going project on white blood cell changes (submitted for
publication). The selected papers were then separated
into studies, further study details being obtained from
additional references if required.
Data entry
Relevant data were entered onto a study and a change
database, each study being identified by a 6-letter refer-
ence (REF). The study database contains one record per
study describing study attributes. The change database
contains one or more records per study, describing esti-
mates of HDL-C change from baseline.
Study attributes recorded include relevant publica-
tions, sexes considered, age range, location, years of
start, finish and publication, length of follow-up, study
design, nature of population studied (including smoking
and medical criteria), study size, HDL-C measurementmethod, fasting or smoking abstinence requirements be-
fore measurement, diet or exercise modification during
follow-up, and confounding and stratifying variables
considered.
Details on the change database include smoking status
(quitter, continuing smoker, never smoker), smoking
habits at baseline and follow-up (products, cigarette
types, amount smoked), biochemical validation methods,
intra-measurement period, original measurement unit,
data source, and population the data applies to (sex, age,
intervention groups). Also recorded is information on
the HDL-C change itself (mean change, or mean level at
both baseline and follow-up), its variability (confidence
limits, SD, SE, N, significance of change) and whether
the change estimate was direct, or relative to never
smokers or to continuing smokers. Where the mean
change was unavailable, the median change, change in
median, or an estimate based on the mean % change was
accepted. Change data were entered for never smokers,
continuing smokers and quitters, but not for smokers
who quit during the follow-up period but resumed be-
fore the second HDL-C measurement. Change data were
converted to mmol/l if necessary. Sex-specific data were
preferred to combined-sex data. Data stratified on other
variables were entered in addition to overall data, includ-
ing stratification by later resumption of smoking, where
available from studies with multiple follow-ups. Available
information on baseline weight, body mass index (BMI)
and other commonly reported physiological parameters,
and on change in weight and BMI, was also recorded.
Statistical analysis
For trials giving results for subjects continuously abstin-
ent since baseline, the quit time was taken as the intra-
measurement period. For other trials, it was estimated
from the study design details. For observational studies,
where quitting could have occurred any time in an inter-
val, the quit time was estimated based on the interval
midpoint.
Non-stratified data were generally selected for analysis
if available, with certain exceptions. Sex-specific data
were preferred to combined-sex data. Where a study
stratified the participants by time successfully quit, with
data for more time points for persistent quitters than for
those resuming smoking by the end of the study, the
stratified data were used. Stratified data were also used
where the levels were relevant to a factor considered in
the heterogeneity analyses (see below). For many studies,
the only estimates available were direct (not relative to
changes in continuing or never smokers) and unadjusted
for covariates. Therefore, to make estimates as compar-
able as possible between studies, direct estimates and
those least adjusted for covariates were selected from
studies providing a choice of estimates.
Table 1 Literature searchesa
PAPERS CITED BY PREVIOUS
REVIEW [4]




MEDLINE SEARCH 6TH July 2012
New abstracts examined 615 → Rejects - total 500
↓ Reason 1 – 442; Reason 3 – 40;
Reason 5 – 7; Reason 6 – 1;
Reason 7 – 7; Reason 8 – 3;
Publications examined 115c → Rejects – total 91
↓ Reason 1 – 80; Reason 3 – 2;
Reason 5 – 1; Reason 6 – 1;
Reason 7 – 5; Reason 8 – 2





New abstracts examined 13 → Rejects – total 7
↓ Reason 1 – 5; Reason 8 – 2
New publications examined 6d → Rejects (reason 1) 6
SECONDARY REFERENCES 15th
August 2012e
New abstracts examined 2 → Rejects (reason 1) 1
↓
New publications examined 1 → Rejects (reason 1) 1
INFORMAL SEARCHING
(including WBC review)
New publications examined 4
↓






aReasons for rejection correspond to study inclusion/exclusion criteria
(see Methods).
bIncludes one paper [11] where HDL-C data not used in the earlier review [4].
cIncludes one paper [12] initially rejected on the basis of the abstract but
found to be relevant when examined for a separate review of WBC.
dOne paper could not be adequately identified, but another paper [13] by the
same author and apparently reporting the same study was substituted.
eChecking continued until no new publications were identified.
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weight and BMI were estimated assuming linearity.
Tertiles of baseline parameters and of change in weight
and in BMI were derived from the combined data on
quitters, continuing smokers and never smokers. The
weight and BMI tertile variables were then merged, pre-
ferring the weight tertile when both were available.
For changes in HDL-C, unweighted and inverse-
variance weighted means and SEs were estimated using
repeated measures analysis of variance, accounting for
serial correlations between changes at different times
within the same group of subjects by the Kenward-
Roger method [9,10]. For weighted analyses, an SE esti-
mate was required for each change. If not provided, it
was calculated from the p-value, 95% confidence interval
(CI), or N and SD combined. Where information on
variability was unavailable, the SE was estimated using
the mean SD for changes where the SD was available.
The analyses of variance were conducted separately
for quitters, continuing smokers and never smokers.
Heterogeneity was investigated by intra-measurement
period, estimated time quit, biochemical validation of
quitting, study characteristics (type, continent, timing,
constraint on diet/exercise), population details (age, sex),
baseline levels of physiological parameters (HDL-C,
LDL-C, triglycerides, systolic and diastolic blood pres-
sure), and aspects of smoking before quitting. Change in
weight was also included as a factor because it was con-
sidered important by several study authors, although in-
terpretation is difficult as, unlike the other factors, this
relates to changes concurrent with the HDL-C changes.
Formal within-study analysis of variation in change by
intra-measurement period or by time quit for studies
providing multiple estimates was not conducted, but
such results if given by study authors are summarized.
To further assess effects of confounding, we compare
change estimates from the same study that are compar-
able apart from level of adjustment. For direct estimates
in quitters, the only possible factors are those relating to
changes following quitting, such as BMI. Estimates rela-
tive to continuing or never smokers (or derived from a
model involving two groups) may involve other factors.
Software
ROELEE Version 3.1 (P.N.Lee Statistics and Computing
Ltd., Sutton, Surrey, UK) was used for data entry and
some statistical analyses, and SAS Version 9.2 (SAS Insti-
tute Inc., Cary, North Carolina, USA) to conduct the re-
peated measures analysis of variance.
Results
Literature searches
Table 1 summarizes the literature searches. 661 papers
were considered, 27 cited by Maeda et al. [4], 615identified from the July 2012 Medline search, 13 from
the August 2012 Cochrane search, and six from other
sources. 508 were rejected by examining abstracts, and
100 by examining full text. This left 53 papers, 47 pro-
viding primary results, and 6 reviews. The 47 primary pa-
pers described 45 distinct studies, one study (GEPNER)
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vided background information.Studies
Table 2 summarizes details of the 45 studies, with fur-
ther detail given in Additional file 1. Countries contrib-
uting the most studies were USA (15) and Japan (7).
Eleven studies were randomized clinical trials (RCTs) of
various smoking cessation treatments, while MOFFA3
was a RCT with an additional community control group.
Twenty were non-randomized smoking cessation studies.
These 32 trials were often small, 18 involving less than
100 subjects, and the largest (ALLEN and GEPNER) some
900. They were often short, 14 presenting results for less
than 10 weeks, and the longest a year. The remaining
studies were observational, three based around commu-
nity health education studies, and ten on routine health
checks or prospective studies. These were larger, most in-
volving some thousands of subjects, and longer, all pre-
senting changes over at least a year, and some for variable
time periods. In particular, study BURNET recruited pre-
menopausal women who returned for follow-up examin-
ation 1 and 2 years after reaching menopause.
Two studies involve persons with CHD risk factors
and one diabetic patients. Seven are studies in people of
low physical activity, and one in participants described
as obese. One study excludes people with low BMI,
while four exclude those with high BMI. Otherwise, pop-
ulations seemed reasonably representative, though some
studies were restricted to heavy or more addicted
smokers, or excluded subjects with defined medical con-
ditions (Additional file 1). Two studies started in the
1970s, 15 in the 1980s (including RAHILL which started
recruitment in 1961 but only measured HDL-C from
1981 onwards), 19 in the 1990s and 9 in the 2000s. De-
scriptions of methods for blood sampling and HDL-C
determination varied considerably, being summarized in
Additional file 1, as are requirements for overnight
fasting and/or smoking abstinence before measurement,
though not all publications provided such details.Changes in HDL-C following quitting
The available data on changes in HDL-C (mmol/l) fol-
lowing quitting are shown in Additional file 2. Two
studies provided no change estimate, merely stating
non-significance at p < 0.05. Study YAMAMO analysed
HDL-C as a dichotomous variable, and reported that sig-
nificantly more quitters than continuing smokers in-
creased their HDL-C level from below to above 40 mg/dl.
The 94 change estimates for the remaining 42 studies pro-
vide the main data set for analysis. They relate to quit
times from 1 day to 157 weeks. For 23 estimates, the SE of
the change was either given or could be derived, while for71 it was estimated from N and an SD estimate (0.263) de-
rived from other studies.
The data concern 53 independent sets of subjects, in-
cluding three from TAMURA, an observational study
presenting results stratified by time between quitting
and follow-up. Four studies provide sets stratified by sex,
three by persistent quitting vs. later resumption, and one
each by exercise training vs. control and by weight gain.
The remaining 32 studies provide one set each. In
addition to TAMURA, thirteen studies provide data on
changes in non-independent multiple periods. The most
intensive study was MOFFA2 presenting results for 11
periods up to 30 days, while four periods were presented
by HAUSTE (up to 26 weeks) and by STUBBE and
VANDEN (up to 52 weeks). Some additional data (not
included in the analysis) are shown in footnotes.
The data are also shown in Figure 1, the x-axis show-
ing time since quitting on a non-linear scale. The inde-
pendent points from TAMURA are joined by a dotted
line, while points for studies contributing multiple non-
independent data are joined by solid lines. For these
studies the available information is insufficient to deter-
mine whether variations between successive follow-ups
are statistically significant, despite about half using re-
peated measures methods to analyze their data.
As seen in Figure 1, several studies show a rapid in-
crease in the first three weeks or so after quitting
(FEHER, MOFFA2-females, STUBBE, SWANK), but lit-
tle or no increase was seen in that time span from other
studies (QUENSE, PULS), the exceptional pattern for
MOFFA2-males showing an increase at day 2 subse-
quently dropping back to only a small increase from
baseline. For quit times longer than 3 weeks, most data
points show an increase in HDL-C, with only five de-
creases, of which only the largest from study KUSHIM
(change −0.138) was significant (p<0.05). Of the longer-
term studies with multiple quit times, some (HAUSTE,
NILSSO, SUWAZO) show quite similar increases at the
different times studied, one (MOFFA1) suggests an in-
creasing change with time, another (MOFFA3, both
sexes) suggests a change only starting after week 5, while
others (ELIAS1, PRIEME, VANDEN) suggest a return
towards baseline after an initial increase.
Table 3 summarizes the repeated measures analyses.
The mean change was 0.107 (95% CI 0.085 to 0.128)
unweighted and 0.060 (95% CI 0.044 to 0.075) weighted,
the difference due to the absence of larger increases (>0.2)
in the longer-term large observational studies (notably
GERACE).
In both unweighted and weighted analysis, there was
significant (p<0.05) variation by intra-measurement pe-
riod. For time quit, the variation was significant only in
the weighted analysis, although the pattern of a lower, but
still significant, increase in the last interval (52+ weeks)
Table 2 Study details
Study REF Source papers Location Study typea Study duration Nb Sexc Baseline yeard
ALLEN [14,15] USA RCT 6 weeks 935 B 1990
BASLER [16] Germany RCT 3 months 139 B 1990
BURNET [17,18] USA Obs 13 years 417 F 1983-84
ELIAS1 [19] Sweden Cess 8 weeks 40 M 1995
ELIAS2 [20] Sweden Cess 16 weeks 58 B 1995-96
FEHER [21,22] UK Cess 2 weekse 30 B 1988
FERRAR [23] USA Cess 4 weeks 10 F 1999
FORTMA [24,25] USA Obs/Int 3 years 40f B 1979-80
GEPNER [26-29] USA RCT 3 years 923 B 2005-07
GERACE [30,31] USA Obs/Int 72 months 3470 M 1973-76
GREEN [32] Israel Obs 1-4 years 968 M 1985-87
HAUSTE [33-35] Germany Cess 6 months 197 M 2001
IINO [36] Japan Cess 12 months 41 B 2002-03
KONDO [12] Japan Cess 4 weeks 29 M 2003
KORHON [37] USA RCT 15 weeks 130 F 2004-07
KUME [38] Japan Obs 3 years 3053 B 2003-07
KUSHIM [39] Japan Obs 5 years 1431 M 1985
LEE [40] Korea Cess 2 months 20 M 2009
LUDVIK [41,42] Iceland RCT 3 months 157 B 1989
MASARE [43] Australia Cess 6 months 64 B 1984
MOFFA1 [44] USA Cess 60 days 36 F 1986
MOFFA2 [11] USA Cess 30 days 45 B 1991
MOFFA3 [45] USA RCT/Comm 77 days 43 B 1999
NIAURA [46] USA RCT 12 weeks 28 F 1996
NILSSO [47] Sweden RCT 4 months 400 B 1994
NORREG [48] Denmark RCT 1 year 225 B 1994
PRIEME [49] Denmark RCT 26 weeks 182 B 1996
PULS [50] Germany Cess 5 weeks 218 B 2003-05
QUENSE [51] Sweden Cess 2 weeks 24 M 1987
RABKIN [52] Canada RCT 2-3 months 140 B 1982
RAHILL [53] USA Obs 30 years 2280g M 1961-70
RICHAR [54] France Cess 3-12 weeks 101 B 1995
SHENNA [55] UK Obs 4 years 41f M 1980-83
STAMFO [56] USA Cess 48 days/1 year 24 F 1984
STUBBE [57] Sweden Cess 6 weeks 21 M 1981
SUWAZO [58] Japan Obs 15 years 7058 M 1991-2002
SWANK [59] USA Cess 7 weeks 19 F 1990
TAMURA [60] Japan Obs/Int 4 years 1102 M 1999-2000
TERRES [61] Germany Cess 24 weeks 121 B 1990-92
TONSTA [62]h Norway RCT 1 year 55 B 1999-2000
VANDEN [63] Netherlands Cess 1 year 106 M 1997-98
YAMAMO [64] Japan Obs 3 years 7321 M 1989
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Table 2 Study details (Continued)
YEH [65,66] USA Obs 5 years 10892 B 1987-89
YOON [67] Korea Obs 12 years 2848 M 1995-2006
ZHANG [68] China Cess 3-6 months 67 M 2009-10
aRCT = randomised controlled trial of a smoking cessation aid or method. RCT/Comm = RCT with community control group. Cess = other smoking cessation
study. Obs/Int = observational study as follow-up to an intervention study (other than of smoking cessation). Obs = other observational study.
bTotal number of subjects in the study.
cB = both sexes, F = females, M = males.
dIf not stated the year before publication is assumed.
eSubjects were studied 2 weeks before and 2 weeks after stopping smoking.
fTotal number not stated, number shown is quitters FORTMA, SHENNA.
gOf the 2280 total participants, 1420 had at least 2 HDL-C measurements. An “observation” was taken as a successive pair of HDL-C measurements. Each person
contributed between 1 and 9 (mean 4) observations to the total of 5895 observations analysed RAHILL.
hResults for a second study also reported by this paper were rejected as the subjects all had documented cardiovascular disease TONSTA.
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(Additional file 3), several other factors showed significant
variation, particularly in the weighted analysis (age, sex,
continent, timing, constraint on diet/exercise, baseline
HDL-C, change in weight/BMI). However many of these
factors are inter-correlated, and correlated with time quit
(e.g. observational studies had longer times and less valid-
ation of quitting or constraint on diet/exercise). In the
further analyses in Table 3, we included time quit in the
model (chosen as perhaps more biologically relevant than
intra-measurement period). Except where based on few
change estimates, increases following quitting were signifi-
cant at each level of each factor. Inclusion of time quit
markedly reduced the number of other factors showing
significant variation between levels, with none significant
in the unweighted analysis. In the weighted analysis, HDL-C
increases were greater (p=0.003) in studies requiring sub-
jects to maintain their pre-quitting diet and exercise habits
than in studies encouraging healthier diets or more exer-
cise, or imposing no constraint. Variation by baseline
HDL-C was significant (p=0.03), but due to smaller
changes in the studies where baseline HDL-C was unavail-
able, rather than to variation between the tertiles. There
was also some evidence (p=0.06), that increases were
greater in those with least weight gain following quitting.
Although no study presented data by amount smoked
or any other aspect of pre-quitting smoking habits, a few
provided data (see footnotes in Additional file 2) on
HDL-C change by other factors, such as age and dose of
nicotine patch. No significant (p<0.05) variation in
change by any such factor was seen.
Several studies provided information on the effect of
confounder adjustment (Table 4). In some, comparison
is only possible between an unadjusted or age-adjusted
estimate and a multiply-adjusted estimate, so inferences
cannot be drawn concerning effects of adjustment for
specific variables. However in two studies (KUSHIM,
SUWAZO) estimates are somewhat higher when ad-
justed for BMI change, in one (STUBBE), the estimate is
lower with adjustment for dietary fat change, while instudy PRIEME adjustment for baseline HDL-C had little
effect on change relative to continuing smokers. The
significance of these differences cannot be assessed.
Changes in continuing smokers and never smokers
Change data for continuing smokers and never smokers
from 20 studies are also shown in Additional file 2. For
both groups the data are reasonably consistent with no
change, and contrast markedly with the quitter data. In
most studies, changes are minor and not significant,
although two large studies (KUSHIM, YEH), which also
surprisingly reported decreases in quitters, reported
large decreases for both never and continuing smokers.
The overall estimates from the repeated measures ana-
lyses (Additional file 3) were not significant except for
the weighted analysis of never smokers, which showed
an overall decrease (change = −0.048, p=0.004), due to
the contributions of KUSHIM, and particularly YEH.
Discussion
Despite considerable between-study variation in design,
methods and populations, and many studies involving
few subjects, the data, with few exceptions, show that
HDL-C increases following quitting. From repeated
measures analysis, mean increases (mmol/l) were 0.107
(95% CI 0.085 to 0.128) unweighted and 0.060 (95% CI
0.044 to 0.075) inverse-variance weighted.
We present some analyses by the period between mea-
surements taken when still smoking and when quit.
However, quitting may not start at baseline, and we also
present analyses by estimated time quit. To derive this,
studies were divided into three types. For cessation trials
with quitters required to be continuously abstinent,
intra-measurement period and time quit are identical.
For other trials, where quitting may not have started im-
mediately, time quit can be derived from the study de-
sign details. For observational studies, where quitting
could have started at any time in an interval, we estimate
time quit from the interval midpoint. This may be
questionable, but should not affect our conclusions.

































Study/stratum with single point weeks
Figure 1 Change in HDL-C by time since quitting. The data are also shown in Additional file 2 (Table A2-1). Independent estimates for
different times from study TAMURA are joined by a dashed line. Non-independent estimates for different times from other studies are joined by
solid lines and distinguished by symbol and colour, as shown in the figure legend. Where there is a single estimate for a study/stratum, this is
shown as a blue diamond: Week 2 FEHER-B, QUENSE-M, PULS-B. Week 4 FERRAR-F, KONDO-M, MOFFA1-F-R, NORREG-B, PRIEME-B-R. Week 5
RICHAR-B. Week 6 ALLEN-B, MASARE-M, MASARE-F. Week 7 STAMFO-F-R. Week 8 ELIAS2-B. Week 9 BASLER-B, LEE-M, NIAURA-F-E, NIAURA-F-C.
Week 10 RABKIN-M, RABKIN-F. Week 12, KORHON-F, TONSTA-B. Week 13 LUDVIK-B. Week 19 ZHANG-M. Week 23 TERRES-B. Week 44 YOON-M-L,
YOON-M-H. Week 52 GEPNER-B. Week 65 GREEN-M. Week 78, FORTMA-B, RAHILL-M, YEH-B. Week 119 SHENNA-M. Week 130 KUSHIM-M. Week 156
GERACE-M. Note that each individual independent point and the start of each group of non-independent points effectively joins back to the (0,0)
point, but this is not shown in the Figure for clarity. Note also that the scale on the x-axis is non-linear (with distances between 13 and 52 weeks
reduced to a quarter, and over 52 weeks to a tenth). Abbreviations: B = both sexes, F = females, M = males; L=low weight gain (<1.3 kg), H=high
weight gain (≥1.3 kg); P = persistent quitter, R = resumed smoking before end of study; E = exercise training intervention, C = control group.
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Table 3 Estimates of change in total HDL-C (mmol/l) following quittinga
Factor Level Nb Unweighted analysis Inverse-variance weighted analysis
Mean (95% CI) pc Mean (95% CI) pc
Overall 94 0.107 (0.085 to 0.128) <0.001 0.060 (0.044 to 0.075) <0.001
Univariate models
Periodd <3 weeks 21 0.102 (0.047 to 0.157) 0.04 0.100 (0.032 to 0.169) <0.001
3 to <6 21 0.102 (0.063 to 0.141) 0.082 (0.042 to 0.123)
6 to <13 20 0.157 (0.119 to 0.194) 0.131 (0.094 to 0.168)
13 to <27 11 0.107 (0.057 to 0.158) 0.108 (0.061 to 0.155)
27 to <52 1 0.100 (−0.068 to 0.268) 0.094 (−0.221 to 0.409)
52+ weeks 20 0.065 (0.027 to 0.102) 0.041 (0.026 to 0.057)
Time quite <3 weeks 23 0.101 (0.050 to 0.152) NS 0.083 (0.030 to 0.137) 0.006
3 to <6 20 0.115 (0.075 to 0.155) 0.112 (0.069 to 0.154)
6 to <13 22 0.145 (0.109 to 0.181) 0.111 (0.075 to 0.148)
13 to <27 9 0.099 (0.042 to 0.156) 0.072 (0.036 to 0.109)
27 to <52 4 0.088 (0.003 to 0.173) 0.058 (−0.004 to 0.121)
52+ weeks 16 0.062 (0.020 to 0.105) 0.040 (0.023 to 0.057)
Models adjusted for time quit
Max Agef <50 years 8 0.124 (0.047 to 0.201) NS 0.161 (0.072 to 0.250) NS
50-70 years 28 0.107 (0.071 to 0.144) 0.065 (0.038 to 0.093)
>70 years 58 0.094 (0.063 to 0.125) 0.080 (0.057 to 0.104)
Sex Male 46 0.090 (0.060 to 0.121) NS 0.073 (0.046 to 0.099) NS
Female 30 0.139 (0.094 to 0.184) 0.123 (0.061 to 0.186)
Combined 18 0.095 (0.052 to 0.138) 0.078 (0.050 to 0.107)
Continent N America 49 0.121 (0.082 to 0.160) NS 0.055 (0.024 to 0.087) NS
Europe 30 0.110 (0.075 to 0.146) 0.096 (0.062 to 0.130)
Asia 13 0.067 (0.016 to 0.118) 0.081 (0.050 to 0.112)
Australia 2 0.026 (−0.099 to 0.152) 0.018 (−0.179 to 0.215)
Timingg <1990 26 0.119 (0.077 to 0.160) NS 0.049 (0.016 to 0.082) 0.08
1990-1999 58 0.100 (0.071 to 0.129) 0.088 (0.065 to 0.110)
2000+ 10 0.071 (0.012 to 0.130) 0.077 (0.040 to 0.114)
Study type Observational 16 0.094 (0.031 to 0.157) NS 0.086 (0.057 to 0.115) NS
RCT 16 0.093 (0.042 to 0.145) 0.090 (0.057 to 0.123)
Other 62 0.108 (0.073 to 0.143) 0.067 (0.040 to 0.093)
Product smoked Any 16 0.102 (0.056 to 0.148) NS 0.103 (0.072 to 0.133) 0.09
Cigarettes 67 0.102 (0.075 to 0.130) 0.069 (0.047 to 0.091)
Cigarettes only 11 0.095 (0.035 to 0.155) 0.092 (0.054 to 0.129)
Validation of quitting Yes 48 0.113 (0.077 to 0.149) NS 0.088 (0.060 to 0.115) NS
No 46 0.092 (0.059 to 0.125) 0.075 (0.051 to 0.098)
Constraint on diet/exercise Stay same 15 0.141 (0.089 to 0.193) 0.09 0.191 (0.126 to 0.255) 0.003
Improve 9 0.135 (0.076 to 0.193) 0.064 (0.036 to 0.092)
No constraint 70 0.087 (0.061 to 0.114) 0.082 (0.066 to 0.099)
Baseline HDL-C 1st tertile 34 0.111 (0.070 to 0.151) NS 0.101 (0.068 to 0.134) 0.03
2nd tertile 25 0.131 (0.083 to 0.178) 0.097 (0.048 to 0.147)
3rd tertile 28 0.100 (0.064 to 0.135) 0.084 (0.061 to 0.108)
unknown 7 0.044 (−0.030 to 0.118) 0.042 (0.010 to 0.073)
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Table 3 Estimates of change in total HDL-C (mmol/l) following quittinga (Continued)
Baseline weight/BMIh 1st tertile 19 0.132 (0.066 to 0.199) NS 0.154 (0.042 to 0.267) NS
2nd tertile 28 0.073 (0.039 to 0.108) 0.073 (0.048 to 0.098)
3rd tertile 21 0.111 (0.060 to 0.163) 0.112 (0.065 to 0.158)
unknown 26 0.120 (0.083 to 0.156) 0.076 (0.047 to 0.105)
Change in weight/BMIh 1st tertile 5 0.155 (0.077 to 0.232) NS 0.161 (0.092 to 0.230) 0.06
2nd tertile 29 0.076 (0.031 to 0.121) 0.074 (0.022 to 0.125)
3rd tertile 51 0.100 (0.073 to 0.128) 0.065 (0.041 to 0.089)
unknown 9 0.105 (0.041 to 0.170) 0.104 (0.042 to 0.166)
Baseline LDL-C 1st tertile 17 0.067 (0.001 to 0.132) NS 0.092 (0.045 to 0.139) NS
2nd tertile 16 0.132 (0.063 to 0.201) 0.084 (0.017 to 0.150)
3rd tertile 17 0.085 (0.039 to 0.130) 0.071 (0.028 to 0.113)
unknown 44 0.110 (0.079 to 0.141) 0.080 (0.054 to 0.106)
Baseline Triglycerides 1st tertile 26 0.134 (0.085 to 0.184) NS 0.099 (0.017 to 0.181) NS
2nd tertile 13 0.108 (0.059 to 0.157) 0.099 (0.034 to 0.163)
3rd tertile 24 0.075 (0.027 to 0.123) 0.079 (0.044 to 0.114)
unknown 31 0.096 (0.062 to 0.130) 0.075 (0.050 to 0.099)
Baseline Systolic BP 1st tertile 8 0.079 (0.015 to 0.142) NS 0.060 (0.006 to 0.115) NS
2nd tertile 7 0.117 (0.046 to 0.188) 0.096 (0.058 to 0.134)
3rd tertile 5 0.066 (−0.016 to 0.148) 0.090 (0.056 to 0.125)
unknown 74 0.107 (0.079 to 0.135) 0.075 (0.052 to 0.098)
Baseline Diastolic BP 1st tertile 8 0.079 (0.015 to 0.142) NS 0.060 (0.006 to 0.115) NS
2nd tertile 7 0.117 (0.046 to 0.188) 0.096 (0.058 to 0.134)
3rd tertile 5 0.066 (−0.016 to 0.148) 0.090 (0.056 to 0.125)
unknown 74 0.107 (0.079 to 0.135) 0.075 (0.052 to 0.098)
aSee Additional file 2 (Table A2-1) for data used on change and SE. Analyses are based on repeated measures analysis of variance using the Kenward-Roger method.
bNumber of estimates that the mean is based on.
cNS p≥0.1. For the overall analysis, this is based on a test for an increase following quitting. For the subgroup analysis, this tests for variation by subgroup level.
dPeriod between first measurement when smoking and second measurement when not smoking (using mean, median or midpoint where necessary).
eBest estimate of time since quit at second measurement.
fMaximum age of population at baseline.
gBased on year of start of study.
hUsing data for weight if both weight and BMI available (see Methods).
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sex, age, location, timing, study type, baseline HDL-C,
baseline weight, increase in weight, or whether quitting
was validated biochemically. Our observation that quit-
ting is associated with increased HDL-C, based on
within-subject changes, is consistent with considerable
evidence of lower HDL-C levels in smokers than quitters
[1,2]. A claim [6] that HDL-C in quitters increases with
increasing time quit is not clearly confirmed by our
analyses. Within the first year following quitting, the in-
crease shows little overall variation by time quit, with
different studies showing different patterns, and
although estimates were lower for longer quit times, this
difference is open to doubt. Notably, two large ob-
servational studies (KUSHIM, YEH) reported a decline
in HDL-C following quitting, and an even larger decline
in continuing smokers and never smokers, resultsinconsistent with other studies. Could some systematic
difference between baseline and follow-up have biased
the estimates of change from these studies, studies
which contributed substantially to the lower estimates
associated with longer-term quitting, and the lower
weighted than unweighted overall estimate.
Previously, Maeda et al. [4], based on far fewer change
estimates, found significantly (p<0.05) higher increases
in HDL-C for females than males. Though our estimate
was also higher for females, we did not find the differ-
ence to be significant. Nor could we repeat their finding
that increases following quitting were significantly
higher in those with higher levels before quitting, though
we did find some trend in that direction. We studied
some factors not considered in the earlier review [4].
The only significant result we found was that increases
were substantially higher in trials where subjects were
Table 4 Effects of adjustment on change in HDL-C (mmol/l) following quittinga
REF Sex or
stratab
Periodc Less adjusted More adjusted
Factors Change Factors Change
GERACEd M 313 (156) none 0.021 age, baseline HDL-C, serum thiocyanate, weight change,
Hegsted score change, medications, alcohol, DBP
0.062
GREENe M 52-209 av 130 (65) age 0.044 + change in BMI, alcohol, coffee, sport 0.044
KUSHIM M 261 (130.5) none −0.138 change in BMI −0.092
PRIEMEd B 4 none 0.122 baseline HDL-C 0.120
RAHILLd M 156 (78)f age 0.026 + baseline HDL-C, LDL-C, diabetes, hypertension, CVD,
CHD, medications
0.041
STUBBE M 2 none 0.238 change in dietary fat 0.179
SUWAZOg M 52 (26) age, day/shift work,
alcohol, exercise
0.044 + change in BMI 0.067
104 (78) 0.065 0.100
156 (130) 0.072 0.098
YOON Mg 52-156 av 88 (44) None 0.045 age, amount smoked, time between measurements,





aData are shown for estimates of change in HDL-C which are equivalent except for the level of adjustment.
bB = both sexes, F = females, M = males; L=low weight gain (<1.3 kg), H=high weight gain (≥1.3 kg).
cPeriod (weeks) between first measurement when smoking and second measurement when quitting. The estimated time quit is shown in parentheses, if
different. “av” = average.
dChange is relative to continuing smokers (change in quitters minus change in continuing smokers) GERACE, PRIEME, RAHILL.
eChange is relative to never smokers (change in quitters minus change in never smokers) GREEN.
fResults are adjusted to 3 year interval RAHILL.
gAdjusted change estimated from a two-group analysis (quitters and continuing smokers) SUWAZO, YOON.
hAdjusted change estimated from a two-group analysis (low and high weight gain) YOON.
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habits (0.191 mmol/l) than in those that encouraged
healthier diets or more exercise (0.064 mmol/l), or stud-
ies that did not impose any constraint (0.082 mmol/l).
Taken together with the non-significant tendency for
higher increases where subjects had less weight gain,
and higher increases when adjusted for weight gain in
two studies, the results suggest a role of diet and weight
gain in mitigating the magnitude of the increase. We
found no clear evidence that increases in HDL-C follow-
ing quitting differed by mean age of subjects in the trial,
study location, product smoked, validation of quitting,
or baseline weight/BMI, all factors not considered earl-
ier [4]. We also found no clear evidence that change
estimates varied systematically by level of confounder
adjustment.
Compared to the previously published meta-analysis
[4] we consider many more studies, and studied ef-
fects of quitting by a much longer list of factors.
However, the evidence considered must still be
regarded as limited in a number of respects. Thus,
many studies involved few subjects, no study provided
data relating the change following quitting to initial
amount smoked, no clinical trial investigated changes overmore than a year, and few studies provided evidence on the
effect of adjustment for confounders. Also, the variability of
changes was often unavailable, and had to be estimated
from other studies. Finally, many studies considered pro-
vided no evidence on changes in continuing smokers and
in never smokers, though the available data are reasonably
consistent with a lack of change, and contrast markedly
with the results for quitters.
The mechanisms by which smoking might decrease or
quitting might increase HDL-C are not fully understood.
One popular explanation [6,69] is that smoking alters
catecholamine release, and hence free fatty acid release,
which in turn affects VLDL and LDL concentrations to
favour their accumulation in blood, contributing to a
lower HDL concentration. However other hypotheses have
been proposed [4,70], involving smoking increasing
cholesteryl ester transfer protein, reducing lecithin choles-
terol acyltransferase activity, affecting apo-1 synthesis, or
increasing triglycerides. It has also been suggested that
some of the change in HDL-C following quitting is due to
associated changes in diet [43,51,56,57], but as mentioned
above our analyses indicated that the increase in HDL-C
tended to be greater in those with least weight gain or
dietary change.
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Quitting smoking is clearly associated with an increase
in HDL-C concentrations. Generally the increase occurs
rapidly, in less than three weeks, with no clear pattern of
change thereafter. This emphasises that some, at least, of
the adverse effects of smoking appear to be rapidly re-
versible on quitting, strengthening the argument for en-
couraging smokers to quit.Additional files
Additional file 1: Further study details. This file presents details,
additional to those shown in Table 2, of the design of each study and
values of baseline characteristics of the study populations.
Additional file 2: Changes in HDL-C, bodyweight and BMI. This file
presents the data on change in HDL-C, body weight and BMI for each
available intra-measurement period, separately for quitters, continuing
smokers and never smokers.
Additional file 3: Further analyses. This file presents results of analyses
of HDL-C change in quitters additional to those shown in Table 3. It also
shows results of equivalent analyses for continuing and never smokers.
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